Literature DB >> 7552614

Doxorubicin for inflammatory breast cancer: a red humor for a red tumor?

C M Legler, D F Hayes.   

Abstract

Entities:  

Mesh：

Substances：

Year:  1995        PMID： 7552614     DOI： 10.1007/bf02307057

Source DB:  PubMed          Journal:  Ann Surg Oncol        ISSN： 1068-9265            Impact factor:   5.344


× No keyword cloud information.
  4 in total

1.  CAF in metastatic breast cancer: standard therapy or another effective regimen?

Authors:  D F Hayes; I C Henderson
Journal:  J Clin Oncol       Date:  1987-10       Impact factor: 44.544

2.  Therapy for inflammatory breast cancer: impact of doxorubicin-based therapy.

Authors:  R L Bauer; E Busch; E Levine; S B Edge
Journal:  Ann Surg Oncol       Date:  1995-07       Impact factor: 5.344

Review 3.  Systemic treatment of early breast cancer by hormonal, cytotoxic, or immune therapy. 133 randomised trials involving 31,000 recurrences and 24,000 deaths among 75,000 women. Early Breast Cancer Trialists' Collaborative Group.

Authors: 
Journal:  Lancet       Date:  1992-01-04       Impact factor: 79.321

Review 4.  Treatment of metastatic breast cancer: present and future prospects.

Authors:  D F Hayes; I C Henderson; C L Shapiro
Journal:  Semin Oncol       Date:  1995-04       Impact factor: 4.929
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.